BACKGROUND: Darunavir 800 mg once daily (QD) is indicated for HIV-1-infected treatment-naïve and treatment-experienced (without darunavir resistance-associated mutations [RAMs]) individuals, and has been evaluated in phase 2/3 studies with durations between 48 and 192 weeks. OBJECTIVE: To summarize the development (or identification) of post-baseline resistance (RAMs and antiretroviral phenotypic susceptibility) among patients receiving darunavir QD dosing. METHODS: Seven phase 2/3 studies with available genotypes/phenotypes for subjects treated with ritonavir- or cobicistat-boosted darunavir 800 mg QD regimens were assessed: ARTEMIS (NCT00258557; n = 343), GS-US-299-0102 (NCT01565850; n = 153), GS-US-216-0130 (NCT01440569; n = 313), ODIN (NCT00524368; n = 294), INROADS (NCT01199939; n = 54), MONET (NCT00458302; n = 256), and PROTEA (NCT01448707; n = 273). Genotypic analyses were conducted at baseline (except switch studies enrolling virologically suppressed subjects [MONET, PROTEA]). Criteria for post-baseline resistance testing and evaluation of the development (or identification [switch studies]) of RAMs (respective IAS-USA mutations) varied slightly across studies. RESULTS: Among 1686 subjects treated with darunavir 800 mg QD regimens, 184 had protocol-defined virologic failure; 182 had post-baseline genotypes analyzed. Overall, 4/1686 (0.2%) developed (or had identified [switch studies]) primary protease inhibitor and/or darunavir RAMs (ARTEMIS, n = 1; GS-US-216-0130, n = 1; ODIN, n = 1; MONET, n = 1). Only 1/1686 (<0.1%) subject lost darunavir phenotypic susceptibility (ODIN; possibly related to prior ritonavir-boosted lopinavir virologic failure). Among 1103 subjects using a nucleos(t)ide reverse transcriptase inhibitor (N[t]RTI) backbone, 10 (0.9%) developed ≥ 1 N(t)RTI RAM (8 had the emtricitabine RAM M184I/V). CONCLUSIONS: Darunavir has a high genetic barrier to resistance. Across a diverse population of HIV-1-infected subjects treated with darunavir 800 mg QD regimens, the development of darunavir resistance was rare (<0.1%).
BACKGROUND:Darunavir 800 mg once daily (QD) is indicated for HIV-1-infected treatment-naïve and treatment-experienced (without darunavir resistance-associated mutations [RAMs]) individuals, and has been evaluated in phase 2/3 studies with durations between 48 and 192 weeks. OBJECTIVE: To summarize the development (or identification) of post-baseline resistance (RAMs and antiretroviral phenotypic susceptibility) among patients receiving darunavir QD dosing. METHODS: Seven phase 2/3 studies with available genotypes/phenotypes for subjects treated with ritonavir- or cobicistat-boosted darunavir 800 mg QD regimens were assessed: ARTEMIS (NCT00258557; n = 343), GS-US-299-0102 (NCT01565850; n = 153), GS-US-216-0130 (NCT01440569; n = 313), ODIN (NCT00524368; n = 294), INROADS (NCT01199939; n = 54), MONET (NCT00458302; n = 256), and PROTEA (NCT01448707; n = 273). Genotypic analyses were conducted at baseline (except switch studies enrolling virologically suppressed subjects [MONET, PROTEA]). Criteria for post-baseline resistance testing and evaluation of the development (or identification [switch studies]) of RAMs (respective IAS-USA mutations) varied slightly across studies. RESULTS: Among 1686 subjects treated with darunavir 800 mg QD regimens, 184 had protocol-defined virologic failure; 182 had post-baseline genotypes analyzed. Overall, 4/1686 (0.2%) developed (or had identified [switch studies]) primary protease inhibitor and/or darunavir RAMs (ARTEMIS, n = 1; GS-US-216-0130, n = 1; ODIN, n = 1; MONET, n = 1). Only 1/1686 (<0.1%) subject lost darunavir phenotypic susceptibility (ODIN; possibly related to prior ritonavir-boosted lopinavir virologic failure). Among 1103 subjects using a nucleos(t)ide reverse transcriptase inhibitor (N[t]RTI) backbone, 10 (0.9%) developed ≥ 1 N(t)RTI RAM (8 had the emtricitabine RAM M184I/V). CONCLUSIONS:Darunavir has a high genetic barrier to resistance. Across a diverse population of HIV-1-infected subjects treated with darunavir 800 mg QD regimens, the development of darunavir resistance was rare (<0.1%).
Entities:
Keywords:
Antiretroviral; Darunavir once daily; Genotypic resistance; Human immunodeficiency virus-1; Phenotypic resistance; Resistance; Resistance-associated mutations
Authors: Joseph J Eron; Chloe Orkin; Joel Gallant; Jean-Michel Molina; Eugenia Negredo; Andrea Antinori; Anthony Mills; Jacques Reynes; Erika Van Landuyt; Erkki Lathouwers; Veerle Hufkens; John Jezorwski; Simon Vanveggel; Magda Opsomer Journal: AIDS Date: 2018-07-17 Impact factor: 4.177
Authors: Gregory D Huhn; Joseph J Eron; Pierre-Marie Girard; Chloe Orkin; Jean-Michel Molina; Edwin DeJesus; Romana Petrovic; Donghan Luo; Erika Van Landuyt; Erkki Lathouwers; Richard E Nettles; Kimberley Brown; Eric Y Wong Journal: AIDS Res Ther Date: 2019-08-29 Impact factor: 2.250
Authors: Yosra A Helmy; Mohamed Fawzy; Ahmed Elaswad; Ahmed Sobieh; Scott P Kenney; Awad A Shehata Journal: J Clin Med Date: 2020-04-24 Impact factor: 4.241
Authors: Erkki Lathouwers; Eric Y Wong; Kimberley Brown; Bryan Baugh; Anne Ghys; John Jezorwski; El Ghazi Mohsine; Erika Van Landuyt; Magda Opsomer; Sandra De Meyer Journal: AIDS Res Hum Retroviruses Date: 2019-10-21 Impact factor: 2.205
Authors: Gregory D Huhn; Gordon Crofoot; Moti Ramgopal; Joseph Gathe; Robert Bolan; Donghan Luo; Richard Bruce Simonson; Richard E Nettles; Carmela Benson; Keith Dunn Journal: Clin Infect Dis Date: 2020-12-15 Impact factor: 9.079
Authors: Kimberley Brown; Lisa Stewart; Jeannette M Whitcomb; Dongmei Yang; Richard E Nettles; Erkki Lathouwers Journal: AIDS Res Hum Retroviruses Date: 2018-10-31 Impact factor: 2.205
Authors: Andrea Antinori; Maria V Cossu; Barbara Menzaghi; Gaetana Sterrantino; Nicola Squillace; Valentina Di Cristo; Annamaria Cattelan; Emanuele Focà; Antonella Castagna; Giancarlo Orofino; Daniela Valenti; Gabriella D'Ettore; Lucia Aprea; Sergio Ferrara; Maria E Locatelli; Giordano Madeddu; Emanuele Pontali; Paolo Scerbo; Barbara Rossetti; Alessia Uglietti; Roberta Termini; Francesco Rucci; Andrea Gori; Daniela Mancusi Journal: Patient Date: 2020-06 Impact factor: 3.883